Dr. Hönle (ETR:HNL) Shares Down 1.2% - Time to Sell?

Key Points

• Shares fell 1.2% to €8.48 mid-day on Thursday after about 1,454 shares traded, trading below the 50‑day SMA (€9.20) but above the 200‑day SMA (€8.17).
• Financials point to a small, loss-making company: market cap is $50.54M, P/E is negative at -3.81 (PEG -0.39), debt/equity is 63.28, with a quick ratio of 0.85 and current ratio of 1.77.
• Business profile: Dr. Hönle supplies industrial UV technologies and systems across three segments—Adhesives, Equipment & Systems, and Glass & Lamps—for markets like electronics, automotive, medical and surface disinfection.

Dr. Hönle AG (ETR:HNL - ) was down 1.2% during mid-day trading on Thursday . The stock traded as low as €8.48 and last traded at €8.48. Approximately 1,454 shares changed hands during mid-day trading, The stock had previously closed at €8.58.

Dr. Hönle Stock Down 1.2%

The company has a debt-to-equity ratio of 63.28, a quick ratio of 0.85 and a current ratio of 1.77. The stock's 50 day simple moving average is €9.20 and its 200 day simple moving average is €8.17. The firm has a market cap of $50.54 million, a P/E ratio of -3.81, a price-to-earnings-growth ratio of -0.39 and a beta of 1.45.

About Dr. Hönle

Dr. Hönle AG engages in the supply of industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, automotive, optics and opto-electronics, medical technology, and glass processing. The Equipment & Systems segment engages in the provision of solutions used for drying inks and coatings, curing adhesives and plastics, disinfecting surfaces, and solar simulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.